Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years.

about

Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years.

Item

http://www.wikidata.org/entity/Q55272311

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Real-World Clinical Effectiven ...... 2 Diabetes for 1 and 2 Years.

@en

Real-World Clinical Effectiven ...... 2 Diabetes for 1 and 2 Years.

@nl

type

Item

label

Real-World Clinical Effectiven ...... 2 Diabetes for 1 and 2 Years.

@en

Real-World Clinical Effectiven ...... 2 Diabetes for 1 and 2 Years.

@nl

prefLabel

Real-World Clinical Effectiven ...... 2 Diabetes for 1 and 2 Years.

@en

Real-World Clinical Effectiven ...... 2 Diabetes for 1 and 2 Years.

@nl

P1476

Real-World Clinical Effectiven ...... e 2 Diabetes for 1 and 2 Years

@en

P2093

Cory Gamble

http://www.w3.org/2001/XMLSchema#string

Michael L Ganz

http://www.w3.org/2001/XMLSchema#string

Rahul Ganguly

http://www.w3.org/2001/XMLSchema#string

Tam Dang-Tan

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Predictive margins with survey data.

Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States.

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study.

Practical considerations on the use of the Charlson comorbidity index with administrative data bases.

A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice.

Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.

P2888

s13300-018-0432-2

P304

1279-1293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13300-018-0432-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Qian Li

P577

2018-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103906557

http://www.w3.org/2001/XMLSchema#string

P698

29744818

http://www.w3.org/2001/XMLSchema#string

P932

5984935

http://www.w3.org/2001/XMLSchema#string